Crossmark

Performance of the SarQoL quality of life tool in a UK population of older people with probable sarcopenia and implications for use in clinical trials: findings from the SarcNet registry

Crossref DOI link: https://doi.org/10.1186/s12877-022-03077-5

Published Online: 2022-04-27

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Witham, Miles D.

Heslop, Philip

Dodds, Richard M.

Clegg, Andrew P.

Hope, Suzy V.

McDonald, Claire

Smithard, David

Storey, Bryony

Tan, Ai Lyn

Thornhill, Anna

Sayer, Avan A.
License Information

Text and Data Mining valid from 2022-04-27

Version of Record valid from 2022-04-27
More Information

Article History

Received: 15 November 2021

Accepted: 18 April 2022

First Online: 27 April 2022

Declarations

:

: The SarcNet study was approved by the North East—Tyne and Wear South NHS Research Ethics Committee (reference 18/NE/0314). Written informed consent was obtained from all participants and the study was conducted according to the principles of the Declaration of Helsinki.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below